Safety of spironolactone use in ambulatory heart failure patients.
Kandula
Praveen
P
Shah
Ravish
R
D000368:Aged; D000553:Ambulatory Care; D015415:Biomarkers / Q000097:blood; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D019317:Evidence-Based Medicine; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006947:Hyperkalemia / Q000097:blood / Q000139:chemically induced*; D007674:Kidney Diseases / Q000097:blood / Q000150:complications*; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000009:adverse effects*; D011188:Potassium / Q000097:blood; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013148:Spironolactone / Q000009:adverse effects*
D015415:Biomarkers; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D003404:Creatinine; D011188:Potassium